内科理论与实践 ›› 2025, Vol. 20 ›› Issue (06): 457-461.doi: 10.16138/j.1673-6087.2025.06.05
陈辉1,*(
), 杨玲1,*, 赵安琪1, 查晴1, 杨克2, 刘艳1,*(
)
收稿日期:2025-01-03
出版日期:2025-12-30
发布日期:2026-01-30
通讯作者:
刘 艳 E-mail:作者简介:*:陈辉与杨玲为并列第一作者
基金资助:
CHEN Hui1,*(
), YANG Ling1,*, ZHAO Anqi1, ZHA Qing1, YANG Ke2, LIU Yan1,*(
)
Received:2025-01-03
Online:2025-12-30
Published:2026-01-30
摘要:
目的:探讨紫花前胡素在动脉粥样硬化疾病中的抗炎作用及其安全性,并验证其对巨噬细胞炎症反应的调节作用。方法:构建高脂饮食喂养的载脂蛋白E基因敲除(apolipoprotein E deficient, ApoE-/-)雄性小鼠动脉粥样硬化模型,通过氧化型低密度脂蛋白(oxidized low-density lipoprotein, oxLDL)刺激RAW 264.7巨噬细胞以诱导泡沫细胞形成。采用油红O(oil red O, ORO)染色评估主动脉斑块面积减少比例。通过蛋白质印迹检测核因子κB(nuclear factor κB, NF-κB)的磷酸化水平,采用炎症因子阵列分析血清及细胞上清中炎症因子水平,并通过苏木精-伊红(hematoxylin-eosin, HE)染色评估紫花前胡素的全身毒性。结果:紫花前胡素显著减少主动脉斑块面积,在oxLDL刺激的巨噬细胞中,其可抑制NF-κB的过度活化,下调促炎因子[如白介素(interleukin, IL)-2和干扰素(interferon, IFN)-γ]的表达,同时上调抗炎因子(如IL-4和IL-10)的水平。此外,在ApoE-/-小鼠模型中,紫花前胡素同样显著降低了血清中促炎因子水平,提高抗炎因子水平。HE染色结果显示,紫花前胡素未对主要器官造成明显的病理损伤。结论:紫花前胡素通过调控巨噬细胞炎症反应发挥显著的抗炎作用,并减轻动脉粥样硬化病变,安全性较高,有望成为治疗动脉粥样硬化的潜在药物。
中图分类号:
陈辉, 杨玲, 赵安琪, 查晴, 杨克, 刘艳. 紫花前胡素在动脉粥样硬化中的抗炎作用及其药物安全性评估[J]. 内科理论与实践, 2025, 20(06): 457-461.
CHEN Hui, YANG Ling, ZHAO Anqi, ZHA Qing, YANG Ke, LIU Yan. Anti-inflammatory effects and safety evaluation of decursin in atherosclerosis[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(06): 457-461.
| [1] |
Lusis AJ. Atherosclerosis[J]. Nature, 2000, 407(6801):233-241.
doi: 10.1038/35025203 |
| [2] | Glass CK, Witztum JL. Atherosclerosis. the road ahead [J]. Cell, 2001, 104(4):503-516. |
| [3] |
Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental?[J]. Cardiovasc Res, 2000, 45(3):736-746.
doi: 10.1016/s0008-6363(99)00235-7 |
| [4] |
Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis[J]. Trends Cardiovasc Med, 2008, 18(6):228-232.
doi: 10.1016/j.tcm.2008.11.004 |
| [5] |
Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis[J]. Cell, 2011, 145(3):341-355.
doi: 10.1016/j.cell.2011.04.005 |
| [6] |
Doran AC, Yurdagul A Jr, Tabas I. Efferocytosis in health and disease[J]. Nat Rev Immunol, 2020, 20(4):254-267.
doi: 10.1038/s41577-019-0240-6 |
| [7] |
Kasikara C, Doran AC, Cai B, et al. The role of non-resolving inflammation in atherosclerosis[J]. J Clin Invest, 2018, 128(7):2713-2723.
doi: 10.1172/JCI97950 |
| [8] |
Yurdagul A Jr, Doran AC, Cai B, et al. Mechanisms and consequences of defective efferocytosis in atherosclerosis[J]. Front Cardiovasc Med, 2018, 4: 86.
doi: 10.3389/fcvm.2017.00086 |
| [9] |
Bank S, Andersen PS, Burisch J, et al. Polymorphisms in the toll-like receptor and the IL-23/IL-17 pathways were associated with susceptibility to inflammatory bowel disease in a Danish cohort[J]. PLoS One, 2015, 10(12):e0145302.
doi: 10.1371/journal.pone.0145302 |
| [10] |
Jiang C, Lee HJ, Li GX, et al. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer[J]. Cancer Res, 2006, 66(1):453-463.
doi: 10.1158/0008-5472.CAN-05-1865 |
| [11] |
Kim JH, Jeong JH, Jeon ST, et al. Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-kappaB activation in macrophages[J]. Mol Pharmacol, 2006, 69(6):1783-1790.
doi: 10.1124/mol.105.021048 |
| [12] |
Kim WJ, Lee MY, Kim JH, et al. Decursinol angelate blocks transmigration and inflammatory activation of cancer cells through inhibition of PI3K, ERK and NF-kappaB activation[J]. Cancer Lett, 2010, 296(1):35-42.
doi: 10.1016/j.canlet.2010.03.012 |
| [13] |
Islam SU, Lee JH, Shehzad A, et al. Decursinol angelate inhibits LPS-induced macrophage polarization through modulation of the NFκB and MAPK signaling pathways[J]. Molecules, 2018, 23(8):1880.
doi: 10.3390/molecules23081880 |
| [14] | National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals, 8th edition [EB/OL]. 2011. https://www.ncbi.nlm.nih.gov/books/NBK54050/. |
| [1] | 唐婷, 王笛, 方威. 胃肠道钙化性纤维性肿瘤5例临床病理分析并文献复习[J]. 诊断学理论与实践, 2026, 25(01): 71-77. |
| [2] | 郭涛, 谢梦雨. 继发性噬血细胞性淋巴组织细胞增多症的诊断与治疗[J]. 诊断学理论与实践, 2026, 25(01): 1-8. |
| [3] | 茆致远 王琛.
四氧化三锰纳米酶促进糖尿病创面愈合的机制研究
[J]. 组织工程与重建外科杂志, 2025, 21(4): 353-. |
| [4] | 杨翠萍, 陈平. 全球炎症性肠病的流行趋势分析及诊治现状[J]. 诊断学理论与实践, 2025, 24(04): 373-382. |
| [5] | 曹芝君, 陆君涛. 炎症性肠病肠外表现的发病机制和处理原则[J]. 内科理论与实践, 2025, 20(02): 112-119. |
| [6] | 葛文松. 炎症性肠病相关肺损伤的诊治策略[J]. 内科理论与实践, 2025, 20(02): 107-111. |
| [7] | 顾于蓓, 洪聿. 炎症性肠病患者缓解期药物降级策略[J]. 内科理论与实践, 2025, 20(02): 101-106. |
| [8] | 曹众, 李春燕, 鲁广生, 等. CX3CR1 对创伤性骨髓炎大鼠骨骼肌微纤维、ERK/MAPK信号通路及炎症反应的影响[J]. 组织工程与重建外科杂志, 2024, 20(1): 58-. |
| [9] | 李晨曦, 胡蕴, 吴文君. 胰腺脂肪沉积与动脉粥样硬化的关联研究进展[J]. 内科理论与实践, 2024, 19(04): 278-282. |
| [10] | 谷天艳, 潘镜余, 陈玲, 邹志浩, 史清海. 炎性细胞因子TNF-α、IL-6、IL-8预测新发脑出血患者预后的价值[J]. 诊断学理论与实践, 2024, 23(04): 405-415. |
| [11] | 刘菂, 瞿洪平, 徐志红, 曹久妹, 郑岚, 白婷婷. 参附注射液对老年脓毒症患者免疫功能的影响[J]. 内科理论与实践, 2024, 19(03): 153-158. |
| [12] | 赵一鸣, 吴棕, 王鲁. 肝脏微环境细胞对结肠直肠癌肝转移的作用[J]. 外科理论与实践, 2024, 29(02): 126-131. |
| [13] | 朱晓雯, 王鸿超, 吴文君. 肠道菌群介导阻塞性睡眠呼吸暂停患者代谢及心血管异常的作用及相关机制进展[J]. 内科理论与实践, 2024, 19(02): 130-135. |
| [14] | 林崴仪, 戈成旺, 唐枭伟, 等. 阿克曼嗜黏液菌外膜蛋白 1100 促进糖尿病大鼠创面愈合 [J]. 组织工程与重建外科杂志, 2023, 19(4): 358-. |
| [15] | 尚思雨, 相阳, 潘博涵.
褐藻寡糖对创面的生物学效应 :裂解程度依赖性
|
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||